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INFLUENCE OF DOXORUBICIN INCLUSION INTO PHOSPHOLIPID 
NANOFORMULATION ON ITS ANTITUMOR ACTIVITY IN MICE: 
INCREASED EFFICIENCY FOR RESISTANT TUMOR MODEL
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Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow 119121, Russia 
Aim: The new formulation of doxorubicin on the base of phospholipid nanoparticles (particle size <30 nm) is elaborated in the 
Institute of Biomedical Chemistry (Russian Academy of Medical Sciences) on the base of plant phospholipids. The aim of study 
is to investigate an antitumor effect of this nanoformulation in mice with two cancer models with various sensitivity to chemo-
therapy — lymphoid malignancy P-388 and Lewis lung carcinoma (LLC). Methods: Nanophospholipid (NPh) formulation of doxo-
rubicin was prepared by homogenization of soybean phosphatidylcholine and doxorubicin hydrochloride. The effect of this formula-
tion was studied in experiments with single or threefold drug administration. Percents of tumor growth inhibition in mice under 
influence of free or NPh doxorubicin forms were compared. Results: Single administration of both free and NPh doxorubicin in mice 
with P-388 resulted in the same quick severe inhibition of tumor growth (60–90% depending from dose), with further gradual 
decrease of inhibition degree. However for more resistant tumor, LLC, the obvious advantage of NPh doxorubicin form was shown. 
The little effect of free doxorubicin began to reveal only after 11 days, but NPh formulation induced significant inhibition of tumor 
growth (40%) from the first experimental point (6 days after administration). The advantages of NPh doxorubicin was manifested 
particularly in low drug doses, 2 and 4 mg/kg. In other experiment design in mice with LLC, with threefold weekly drug administra-
tion, NPh doxorubicin appeared to be 2.5 times more active than free drug. The reason of the same actions of free and NPh doxo-
rubicin form in P-388 is suggested the high drug sensitivity of this model, that gives quick high drug response for any doxorubicin 
form. Conclusion: Doxorubicin in phospholipids nanoformulation revealed higher antitumor efficiency as compared with free 
doxorubicin in mice with LLC carcinoma. The mechanism of such changes is supposed to be caused by increase of doxorubicin 
availability for cancer cells. 
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Inclusion of drugs into different transport systems 
�ased on polymers or lipids� is the modern way to in-
crease their �ioavaila�ility and efficiency [�� �]. For 
oncology field such systems are considered to �e par-
ticularly urgent� �ecause they promote the overcoming 
of side effects that are relevant to antitumor drugs [�]. 
Many researches are devoted to developing of new 
forms of doxoru�icin — an effective cytostatic� �ut 
with severe side effects� particularly cardiotoxicity 
[�� 5]. There are some liposomal forms of doxoru�icin 
in pharmaceutical market� although they have also 
some disadvantages. So� the sta�ilized form of liposo-
mal doxoru�icin �“�oxil”� may reveal some additional 
side effects as result of presence of polyethylene gly-
col [�]� and other liposomal form� Myocet �TLC �-99�� 
is removed rapidly from circulation �y RES �ecause 
of relatively large liposome sizes ��5���8� nm� [5]. 
The new forms of doxoru�icin in polymer-drug conju-
gates on �ase of the �hydroxypropyl�methacrylamide 
copolymers �PK�� PK�� are now in clinical trials and 
showed the decrease of side effects [�]. In the same 
time� the development of new technologies� that gave 
the new carrier type — phospholipid nanoparticles [7� 
8]� allows to return to phospholipids as to the most 
natural su�stances [9] with possi�ility of their usage 
as potential carriers for doxoru�icin� �ut yet on new 
modern� nanomedicine� level. The use of phospholipid 
nanoparticles may give possi�ilities to utilize the ad-
vantages of liposomes as �iocompati�le carriers [9]� 
�ut without their weaknesses [�� �� 8]. 
We have previously shown the increase of antitu-
mor activity of doxoru�icin �y means of its inclusion 
into 5���� nm phospholipid nanoparticles� sta�ilized 
�y glycyrrhizic acid �the drug Phosphogliv� [��]. Then� 
the inclusion of doxoru�icin into other nanophospho-
lipid �NPh� transport system� without other additive 
components and with particle size ����� nm� was de-
scri�ed [��]. The em�edding of a num�er of drugs into 
such nanoparticles resulted in improvement of their 
pharmacokinetics or/and changes of interaction with 
�lood components [8]. For doxoru�icin such inclu-
sion decreased drug association with erythrocytes 
in incu�ation in vitro with �lood� that increased the part 
of availa�le drug in plasma [��]. �rug redistri�ution 
from plasma proteins �al�umin� fraction to high density 
lipoproteins �H�L� was also shown [��]. It may �e sug-
gested to stimulate doxoru�icin delivery to cancer 
cells — through interaction with receptors — SRB� or� 
after drug redistri�ution� B�E-receptors� that is known 
to �e highly expressed in a num�er of tumors [��� ��] 
The aim of this study was to investigate the 
antitumor activity of doxoru�icin em�edded in ���
�� nm phospholipid nanoparticles on tumor models. 
In order to evaluate possi�le influence of tumor resis-
tance varia�ility on its response to NPh doxoru�icin 
formulation� two tumor mice models with known 
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different response to chemotherapy were used — 
Lewis lung carcinoma �LLC� and lymphoid malignancy 
P-�88. The later is known as one of the most sensitive 
tumors — fewer than �% of all agents active against 
P�88 showed significant effects in other more resis-
tant models [�5� ��]. LLC revealed higher resistance 
for a num�er of drugs [�7� �8]. �ifferent responses 
of these two models for the same drugs suggested the 
necessity to study their responses for new doxoru�icin 
nanoformulation — for the more distinct elucidation 
of the field of its efficiency. 
MATERIALS AND METHODS
NPh formulation of doxoru�icin was prepared ac-
cording to the original technology with homogeniza-
tion� as detailed in the invention [��]. Soy�ean phos-
phatidylcholine Lipoid S��� �Lipoid Gm�H� Germany� 
and doxoru�icin hydrochloride ��ian Jiang� Chong 
Qing� China� were used. The particle size was not more 
than �� nm. The degree of �inding of doxoru�icin with 
phospholipid particles was 98% [��]. The medicinal 
preparation �oxoru�icin-LANS �“LANS-Pharm”� Rus-
sia� was used as free drug. 
Antitumor effects of NPh doxoru�icin were stu-
died on Bal�/c mice weigting ����5 g inoculated 
with two tumor strains — LLC and lymphoid leukemia 
P-�88 �solid form�� o�tained from N.N. Blokhin Russian 
Oncology Center and maintained in the same animals 
in P.A. Gertsen Moscow Scientific Oncology Institute. 
Tumors were transplanted to mice su�cutaneously: for 
P-�88 — ��� tumor cells in �.� ml of �.9% NaCl� for 
LLC — �5 mg of tumor tissue in �.� ml of �.9% NaCl. 
�oxoru�icin preparations in NPh or free forms 
were administered �y single intravenous injections 
in the doses of �; �; 8 or �� mg/kg to mice with 
P-�88 in �� h after tumor cell inoculation and to mice 
with LLC — in �8 h after tumor transplantation. Anti-
tumor efficacy was monitored �y inhi�ition of tumor 
growth �% from control� within ����8 days. Experi-
ments with long-term treatment regimen were also 
carried out in mice with LLC. Both doxoru�icin prepara-
tions �free or NPh� in dose 5 mg/kg were administered 
intraperitoneally weekly — three times� starting � week 
after tumor transplantation. Tumor dimensions were 
measured on ��nd day after transplantation. The per-
cent of inhi�ition of tumor growth in comparison with 
control �untreated� animal group was calculated. Each 
group of animals included ����� animals.
The statistical analysis of the o�tained data has 
�een carried out using standard Student’s t-criterion. 
All experiments were carried out in accordance with 
demands of Russia National Bioethic Committee� 
on the �ase of “Ethical and law pro�lems of clinical 
trials and scientific experiments with human and 
animals” �M.� �99��� that corresponds to international 
standards of animal welfare.
RESULTS AND DISCUSSION
The effect of doxoru�icin treatment appeared 
to �e su�stantially different for two tumor models from 
the very �eginning of experiment �Fig. �� a� b�. 
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Fig. 1. Inhi�ition of tumor growth in mice as compared with 
control animals after single administration of free or NPh doxo-
ru�icin forms: a� lymphoid malignancy P-�88 �� — �� mg/kg� 
� — � mg/kg �� b� LLC �� mg/kg �. Solid curves — NPh doxoru-
�icin� dashed curves — free doxoru�icin 
For P-�88 �Fig. �� a� �oth drug forms induced signifi-
cant inhi�ition of tumor growth in the first experimental 
point �5 days after administration� — ����5% at dose 
� mg/kg� and 88�9�% at �� mg/kg. The effects of in-
termediate doses� � and 8 mg/kg� were similar �data not 
shown�. The use of NPh form did not increase doxoru-
�icin efficiency in this tumor model. It may �e caused 
possi�ly �y the fact that the limit of maximal doxoru�icin 
effect for this sensitive tumor has �een already reached 
quickly in the case of free drug. This assumption is con-
firmed �y the decrease of inhi�ition percent in the next 
days — till �����% to ��th days �Fig. �� a�� as result 
of possi�ility of quick maximal response of this tumor 
model to administered drug [�5� ��].
In contrary� for mice with LLC �Fig. �� b� su�stantial 
differences in efficiency of two doxoru�icin forms were 
o�served� and effect of NPh doxoru�icin appeared 
to �e significantly higher. Free doxoru�icin �� mg/kg� 
had any effect within 8�9 days of experiment� and 
it was only from ��th day� when a little inhi�ition of tumor 
growth �egan ���%�. But NPh doxoru�icin induced sig-
nificant inhi�ition of tumor growth ���%� from the first 
experimental time point �� days after administration�. 
Unlike to P-�88 tumor �Fig. �� a�� LLC growth inhi�ition 
�Fig. �� b� in next experimental days did not decrease� 
�ut oppositely — gradually elevated. It testifies that the 
�eginning of doxoru�icin effect in LLC reflects gradual 
drug accumulation in tumor tissue� and NPh drug form 
accelerates this process. 
One of the mechanisms of increase of antitumor 
activity of NPh doxoru�icin as compared with free 
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drug is suggested the a�ility to modulate doxoru�i-
cin delivery in tumor. The quantity of drug in cancer 
cells� that is necessary for �eginning of its action� 
is reached earlier and at lower doses for doxoru�icin 
in phospholipid nanoparticles� than for free drug. But 
for the sensitive tumor P-�88 even little drug quantity 
is sufficient for the great growth inhi�ition. It is not 
excluded� that possi�le differences in response for 
NPh doxoru�icin could �e also revealed for this tumor� 
�ut at lower drug doses. The mechanism of different 
sensitivity of tumor models are suggested to �e as-
sociated with some morphological and/or �iochemi-
cal characteristics [�9���]. For example� there are 
data a�out possi�le association of tumor sensitivity 
with such factors as activity of cathepsins B� L and �� 
causing degradation of cellular matrix [�9]� or vascular 
endothelial growth factor [��]� or P-glycoprotein [��]� 
or enzyme dihydrodiol dehydrogenase ���H� [�8]. 
For treatment of LLC the advantage of NPh doxo-
ru�icin form as compared with free doxoru�icin has 
�een revealed particularly at low drug doses �� and 
� mg/kg�� when the action of free doxoru�icin didn’t yet 
manifest itself �Fig. ��. It should �e noted� that such 
doses are more close to those used in the clinic 
������ mg/m� every � weeks� i. e.� �.���.� mg/kg [��� 
��]�. Fig. � demonstrates also� that the same extent 
of tumor growth inhi�ition �~���5�% after 8 days� 
is achieved for NPh doxoru�icin at �.5�� times lower 
doses ���� mg/kg�� than for free drug ���8 mg/kg�. 
It is important �ecause of known doxoru�icin side 
effects [�� 5].
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Fig. 2. �ependence of tumor growth inhi�ition in mice with LLC 
tumor from doxoru�icin doses in free and in NPh forms �8 days 
after single administration�. Solid curves — NPh doxoru�icin� 
dashed curves — free doxoru�icin 
The results for LLC model demonstrated also the 
gradual smoothing of distinctions �etween free and 
NPh drug forms with increase either of doses �Fig. �� 
or of experiment duration �Fig. �� b�. It confirms the 
assumption� that the reason of stimulating influence 
of phospholipid nanoparticles is their a�ility to modu-
late doxoru�icin accumulation in tumor �y increase 
of drug �ioavaila�ility [�� �� ��]. The quantity of drug 
in cancer cells� that is necessary for �eginning of its 
action is reached earlier and at lower doses for doxoru-
�icin in phospholipid nanoparticles� than for free drug. 
Pronounced advantage of NPh form of doxoru�icin 
was o�served more nota�ly in other experimental set-
ting — after three times weekly administration of drugs 
in the dose of 5 mg/kg to mice with LLC �Ta�le ��. After 
treatment with free doxoru�icin the average tumor 
volume was 5�9� mm� �compared to �7�� mm� in the 
control group�� i. e. growth inhi�ition was only ��%. 
But administration of NPh doxoru�icin resulted in more 
than �-fold greater effect� causing growth inhi�ition 
�y 5�% �tumor volume �9�� mm��.
There are several possi�le mechanisms promoting 
doxoru�icin delivery to cancer cells after inclusion 
into phospholipids nanoparticles. It may �e related 
to its decreased �inding with �lood cells and proteins 
and correspondent redistri�ution to lipoproteins� that 
we have shown earlier for this doxoru�icin form [��]. 
As others possi�le contri�uting factors one can as-
sume the penetration of phospholipid nanoparticles 
through defects of tumor vessels �EPR effect� [��]� 
or the overcoming of multidrug resistance �M�R� �ar-
rier� as it was shown recently for phospholipid-coated 
solid lipid nanoparticles �SLN� [�5]. The possi�i lity 
of endocytosis of nanoparticles �ecause of their 
nanosize [��] may also �e supposed. The positive 
influence of phospholipid particles nanosize is con-
firmed �y more pronounced effect of NPh doxoru�icin 
in this study ��-fold� Ta�le �� as compared with our 
previous results for doxoru�icin in other phospholipid 
nanoparticles� with the size of 5���� nm� in the same 
experimental conditions �tumor model� dose and treat-
ment scheme� — only ��% [��]. 
Table. Inhibition of tumor growth in mice with LLC tumor after 3-times week-
ly administration of free doxorubicin or its NPh form
Animals groups Tumor vo-lume, mm3
Tumor growth 
inhibition per-
cent* (%)
1. Control (n = 10) 6713 ± 453 —
2. Administration of free doxorubicin (n = 11) 5390 ± 389 20.0 ± 5.6
3. Administration of NPh doxorubicin (n= 13) 2934 ± 182   
P3–2 <0.001
56.1 ± 3.8   
P3–2 <0.001
Notes: Doxorubicin preparations were administered intraperitoneally in the 
dose of 5 mg/kg weekly — three times, starting 7 days after tumor trans-
plantation. Tumor dimensions were measured on 22nd day after transplan-
tation. * differences are significant as compared with control group values 
Thus� treatment with doxoru�icin in nanoformula-
tion of natural phospholipids� o�tained as the ultra-fine 
emulsion with a particle size less than �� nm [��]� has 
demonstrated in mice with LLC su�stantially higher 
antitumor efficiency as compared with free doxoru�i-
cin� despite of a�sence of such effect in more sensitive 
tumor model� lymphoid malignancy P-�88. Preferential 
effect of NPh doxoru�icin as compared with free drug 
in LLC tumor was especially nota�le at low drug doses 
and particularly at the regimen of repeated weekly 
administrations. The results confirm the necessity 
to take into consideration the sensitivity or resistance 
of various used tumor models in the ela�oration of new 
forms of drug delivery [�5]� and also testify to possi�le 
potential prospectivity of NPh form of doxoru�icin for 
tumors with poor response to therapy. The treatment 
of such tumors may require high doses of cytostatics� 
which may �e often impossi�le �ecause of their se-
vere side effects� and in this case replacement of free 
doxoru�icin for its NPh form could �e advisa�le. 
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